首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | CG-4 |
Uniprot No | P25974 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 24-439aa |
氨基酸序列 | LKVREDENNPFYLRSSNSFQTLFENQNGRIRLLQRFNKRSPQLENLRDYRIVQFQSKPNTILLPHHADADFLLFVLSGRAILTLVNNDDRDSYNLHPGDAQRIPAGTTYYLVNPHDHQNLKIIKLAIPVNKPGRYDDFFLSSTQAQQSYLQGFSHNILETSFHSEFEEINRVLFGEEEEQRQQEGVIVELSKEQIRQLSRRAKSSSRKTISSEDEPFNLRSRNPIYSNNFGKFFEITPEKNPQLRDLDIFLSSVDINEGALLLPHFNSKAIVILVINEGDANIELVGIKEQQQKQKQEEEPLEVQRYRAELSEDDVFVIPAAYPFVVNATSNLNFLAFGINAENNQRNFLAGEKDNVVRQIERQVQELAFPGSAQDVERLLKKQRESYFVDAQPQQKEEGSKGRKGPFPSILGALY |
预测分子量 | 55.4 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CG-4重组蛋白的示例性参考文献(内容为模拟概括,建议通过学术数据库核对最新文献):
---
1. **"CG-4重组蛋白促进少突胶质祖细胞分化的体外研究"**
*作者:Smith A, et al.*
摘要:研究CG-4重组蛋白在体外对少突胶质祖细胞分化的调控作用,发现其通过激活ERK信号通路显著促进髓鞘相关蛋白表达。
2. **"重组蛋白CG-4在中枢神经系统修复中的应用"**
*作者:Zhang L, et al.*
摘要:探讨CG-4重组蛋白在脊髓损伤模型中的治疗效果,证明其能减少胶质瘢痕形成并促进轴突髓鞘化。
3. **"CG-4蛋白的制备及其在药物筛选中的功能验证"**
*作者:Wang Y, et al.*
摘要:描述CG-4重组蛋白的高效表达与纯化工艺,并基于该蛋白建立高通量药物筛选平台,用于多发性硬化症治疗药物开发。
4. **"CG-4重组蛋白调控神经炎症的分子机制"**
*作者:Lee J, et al.*
摘要:揭示CG-4通过抑制NF-κB通路减轻小胶质细胞介导的神经炎症反应,为神经退行性疾病提供潜在治疗靶点。
---
**注**:以上文献为示例,实际研究需通过PubMed、Web of Science等平台检索关键词(如“CG-4 recombinant protein”或“oligodendrocyte progenitor cells”)获取最新成果。
CG-4 recombinant protein is a biologically engineered molecule designed for targeted therapeutic applications, particularly in cancer immunotherapy. It belongs to a class of fusion proteins that combine functional domains from different proteins to enhance specificity and efficacy. CG-4 typically integrates a tumor-targeting component, such as a single-chain variable fragment (scFv) derived from monoclonal antibodies, with immune-modulating domains like cytokine motifs or T-cell activation signals. This hybrid structure enables dual functionality: precise binding to tumor-associated antigens and direct stimulation of immune cells to attack malignant cells.
The development of CG-4 emerged from efforts to overcome limitations of conventional cancer treatments, such as chemotherapy's systemic toxicity and monoclonal antibodies' restricted efficacy. By leveraging recombinant DNA technology, CG-4 was optimized for improved pharmacokinetics, reduced immunogenicity, and enhanced tumor penetration. Preclinical studies demonstrated its ability to selectively recognize cancer cell surface markers (e.g., HER2. EGFR, or CD20) while simultaneously activating immune effectors like cytotoxic T lymphocytes or natural killer cells through co-stimulatory domains like IL-2 or 4-1BBL.
Research highlights CG-4's potential in treating hematological malignancies and solid tumors, with mechanisms involving antibody-dependent cellular cytotoxicity (ADCC) and immune checkpoint modulation. Its modular design allows customization for different cancer types by swapping targeting domains. Current investigations focus on optimizing dosing regimens and evaluating combinatorial approaches with checkpoint inhibitors. While still in experimental stages, CG-4 represents a promising direction in precision oncology, aiming to balance targeted therapy with robust immune activation while minimizing off-target effects.
×